Intravenous Thrombolytic Therapy for Acute Ischemic Stroke: Results of Large, Randomized Clinical Trials

[1]  M. Wintermark,et al.  Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[2]  Geoff Cohen,et al.  The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial , 2012, The Lancet.

[3]  Geoff Cohen,et al.  Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis , 2012, The Lancet.

[4]  G. Donnan,et al.  A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. , 2012, The New England journal of medicine.

[5]  A. Buchan,et al.  Thrombolysis at 3–4.5 Hours after Acute Ischemic Stroke Onset – Evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) Registry , 2010, Cerebrovascular Diseases.

[6]  J. Grotta,et al.  Phase IIB/III Trial of Tenecteplase in Acute Ischemic Stroke: Results of a Prematurely Terminated Randomized Clinical Trial , 2010, Stroke.

[7]  Jeffrey L Saver,et al.  Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. , 2009, Stroke.

[8]  Keith Muir,et al.  Thrombolysis with alteplase 3–4·5 h after acute ischaemic stroke (SITS-ISTR): an observational study , 2008, The Lancet.

[9]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[10]  H. Kaufman,et al.  Non-penetrating trauma to the carotid artery with secondary thrombosis and embolism: Treatment by Thrombolysin , 2005, Acta Neurochirurgica.

[11]  Scott Hamilton,et al.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , 2004, The Lancet.

[12]  E. Ringelstein,et al.  Local intraarterial fibrinolytic therapy in inaccessible internal carotid occlusion , 1984, Neuroradiology.

[13]  G. D. Graham,et al.  Tissue Plasminogen Activator for Acute Ischemic Stroke in Clinical Practice: A Meta-Analysis of Safety Data , 2003, Stroke.

[14]  J. Grotta,et al.  Early stroke treatment associated with better outcome: the ninds rt-pa stroke study , 2000, Neurology.

[15]  A. Buchan,et al.  The Canadian Activase for Stroke Effectiveness Study (CASES): Interim results , 2000 .

[16]  S Hamilton,et al.  The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. , 2000, Stroke.

[17]  G. Albers,et al.  Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. , 2000, JAMA.

[18]  G. Albers,et al.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.

[19]  M. Kaste,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.

[20]  W. Hacke,et al.  Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set: post hoc analysis of ECASS I. , 1998, Stroke.

[21]  B. Tilley,et al.  Myths regarding the NINDS rt-PA Stroke Trial: setting the record straight. , 1997, Annals of emergency medicine.

[22]  G. Hankey,et al.  Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. , 1996, Journal of the American Medical Association (JAMA).

[23]  M. Hommel,et al.  Thrombolytic therapy with streptokinase in acute ischemic stroke. , 1996, The New England journal of medicine.

[24]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[25]  L. Munari,et al.  RANDOMIZED CONTROLLED TRIAL OF STREPTOKINASE, ASPIRIN, AND COMBINATION OF BOTH IN TREATMENT OF ACUTE ISCHEMIC STROKE , 1995 .

[26]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.

[27]  G. Hankey,et al.  Trials of streptokinase in severe acute ischaemic stroke , 1995, The Lancet.

[28]  K. Lees,et al.  Termination of trial of streptokinase in severe acute ischaemic stroke , 1995, The Lancet.

[29]  J. Marler,et al.  Urgent Therapy for Stroke: Part II. Pilot Study of Tissue Plasminogen Activator Administered 91-180 Minutes From Onset , 1992, Stroke.

[30]  J. Broderick,et al.  Urgent Therapy for Stroke: Part I. Pilot Study of Tissue Plasminogen Activator Administered Within 90 Minutes , 1992, Stroke.

[31]  R. Fears.  Biochemical pharmacology and therapeutic aspects of thrombolytic agents. , 1990, Pharmacological reviews.

[32]  L. Wechsler,et al.  Intracranial thrombolysis via a catheter embedded in the clot. , 1989, Stroke.

[33]  P. Lyden,et al.  Tissue Plasminogen Activator: Reduction of Neurologic Damage After Experimental Embolic Stroke , 1988 .

[34]  U. Tebbe,et al.  LYSIS OF BASILAR ARTERY OCCLUSION WITH TISSUE PLASMINOGEN ACTIVATOR , 1987, The Lancet.

[35]  G. Agnelli,et al.  Thrombolytic Therapy for Thromboembolism of Vertebrobasilar Artery , 1983, Angiology.

[36]  E. Ringelstein,et al.  Local intraarterial thrombolysis in vertebrobasilar thromboembolic disease. , 1983, AJNR. American journal of neuroradiology.

[37]  M. Laprevote-Heully,et al.  [Indications for the use of thrombolytics in cases of cerebrovascular thrombosis also treated with hyperbaric oxygenation (2 ATA)]. , 1977, Therapie.

[38]  M. Raichle,et al.  A Pilot Study of Urokinase Therapy in Cerebral Infarction , 1976, Stroke.

[39]  Radford Aj,et al.  Letter: Malignant kwashiorkor. , 1974 .

[40]  J. F. Johnson,et al.  ANTICOAGULANTS PLUS STREPTOKINASE THERAPY IN PROGRESSIVE STROKE. , 1964, JAMA.

[41]  J. F. Johnson,et al.  Therapeutic thrombolysis in cerebral thromboembolism , 1963, Neurology.

[42]  J. F. Johnson,et al.  Fibrinolysin therapy in thrombotic diseases of the nervous system. , 1960, Journal - Michigan State Medical Society.

[43]  R. L. Clarke,et al.  The treatment of cerebrovascular thromboses and embolism with fibrinolytic agents. , 1960, The American journal of cardiology.